Sociedad Americana de Hirudoterapia

Clinical outcomes and a high prevalence of abnormalities on comprehensive arterial and venous thrombophilia screening in TIA or ischaemic stroke patients with a patent foramen ovale, an inter-atrial septal aneurysm or both

Research article published in Journal of the neurological sciences (2017)

Última actualización: June 18, 2026Revisado por: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Research reportEnsayos clínicosResistencia antimicrobianaLim ST et al. · Journal of the neurological sciences, 2017

Abstract

INTRODUCTION: Data are limited on the optimal management of cryptogenic TIA/stroke patients with a patent foramen ovale (PFO)±inter-atrial septal aneurysm (IASA), especially with an inherited thrombophilia. METHODS: Prospectively-collected data on TIA/ischaemic stroke patients with PFO, IASA or both who received 'goal-directed secondary-prevention medical treatment' were analysed. All patients had trans-oesophageal echocardiography, anti-nuclear, anti-cardiolipin, anti-beta 2 glycoprotein I antibodies, rheumatoid factor, lupus anticoagulant, protein C&S, anti-thrombin, factor VIII activity, activated protein C resistance, Factor V Leiden, prothrombin gene and MTHFR-c.677C>T mutation screening. ENA and homocysteine were assessed in the latter study period. RESULTS: Eighty-three patients were recruited. Mean follow-up: 48.1months. Forty-seven patients (56.6%) had an isolated PFO, 32 (38.6%) a PFO and an IASA, and 4 (4.8%) an IASA alone. Eighteen (21.7%) had ≥1 abnormality on thrombophilia screening. The most important abnormalities which lead to treatment changes in 11 patients (13.3%) were primary anti-phospholipid syndrome (N=3; 3.6%), protein S deficiency (N=2; 2.4%) hyper-homocysteinaemia (N=6/72 screened, 8.3%). Four patients (4.8%) opted for PFO closure: two with protein S deficiency, and two with no identified thrombophilia. Seven (8.4%) had recurrent TIA/ischaemic stroke during follow-up (overall annualised incidence: 2.1%), of whom five had a PFO alone and two a PFO and IASA. DISCUSSION: Comprehensive arterial and venous thrombophilia screening is warranted in TIA/ischaemic stroke patients with a PFO±IASA, is conclusively abnormal in over a fifth, and informed important decision-making regarding individualised therapy in 13.3% of patients. The incidence of recurrent vascular events in this population is low on optimal, personalised secondary-prevention treatment, even with an underlying thrombophilia.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal Article
Indexed MeSH termsAdultAgedEchocardiographyFemaleFibrinolytic AgentsForamen Ovale, PatentHeart Septal Defects, VentricularHumansIschemic Attack, TransientLongitudinal StudiesMaleMiddle Aged

Resumen

Data are limited on the optimal management of cryptogenic TIA/stroke patients with a patent foramen ovale (PFO)±inter-atrial septal aneurysm (IASA), especially with an inherited thrombophilia. Prospectively-collected data on TIA/ischaemic stroke patients with PFO, IASA or both who received 'goal-directed secondary-prevention medical treatment' were analysed.

Por qué esto importa para la hirudoterapia

Este estudio observacional prospectivo siguió a 83 pacientes con AIT/ictus isquémico que presentaban un foramen oval permeable y/o aneurisma del septo interauricular y se sometieron a un cribado exhaustivo de trombofilia arterial y venosa; más de una quinta parte presentaba al menos una anomalía, el cribado alteró el manejo en el 13.3% de los pacientes, y los eventos vasculares recurrentes fueron bajos (incidencia anualizada del 2.1%) con un tratamiento individualizado de prevención secundaria. Para la ASH, esto se enmarca en el panorama más amplio de la evidencia sobre trombosis/anticoagulación en lugar de abordar directamente la terapia con sanguijuelas: documenta cómo las trombofilias heredadas y adquiridas moldean las decisiones antitrombóticas, el mismo territorio clínico en el que se sitúan conceptualmente los agentes antitrombóticos naturales como la hirudin derivada de sanguijuelas. La advertencia es que se trata de una cohorte observacional unicéntrica con una muestra modesta centrada en el manejo del ictus por PFO/IASA, no hace ninguna mención a la hirudoterapia, y sus hallazgos sobre el rendimiento del cribado y la recurrencia son específicos de esa población seleccionada.

Citación

Clinical outcomes and a high prevalence of abnormalities on comprehensive arterial and venous thrombophilia screening in TIA or ischaemic stroke patients with a patent foramen ovale, an inter-atrial septal aneurysm or both.

Lim ST et al. · Journal of the neurological sciences, 2017

Contexto clínico relacionado

Añadido a la biblioteca ASH: May 28, 2026 · Última actualización del sitio: June 18, 2026

Este sitio web proporciona información educativa y no constituye consejo médico, diagnóstico ni recomendaciones de tratamiento. La terapia con sanguijuelas medicinales conlleva riesgos clínicamente significativos y debe ser realizada únicamente por profesionales calificados bajo protocolos aprobados institucionalmente. La autorización 510(k) de la FDA para sanguijuelas medicinales se limita a indicaciones específicas; las discusiones sobre uso investigativo y fuera de indicación se señalan correspondientemente. Para orientación médica específica, consulte a un profesional de salud calificado.